KR20000036039A - 방출 조절된 [Ｒ-(Ｚ)]-α-(메톡시이미노)-α-(1-아자비시클 - Google Patents

방출 조절된 [Ｒ-(Ｚ)]-α-(메톡시이미노)-α-(1-아자비시클 Download PDF

Info

Publication number
KR20000036039A
KR20000036039A KR1019997002030A KR19997002030A KR20000036039A KR 20000036039 A KR20000036039 A KR 20000036039A KR 1019997002030 A KR1019997002030 A KR 1019997002030A KR 19997002030 A KR19997002030 A KR 19997002030A KR 20000036039 A KR20000036039 A KR 20000036039A
Authority
KR
South Korea
Prior art keywords
formulation
compound
controlled release
coated
polymer
Prior art date
Application number
KR1019997002030A
Other languages
English (en)
Korean (ko)
Inventor
수잔 마리 밀로소비치
윌리엄 멀둔
제임스 앨버트 내이퍼
로렌스 루소
조지프 사우어
Original Assignee
피터 기딩스
스미스클라인비이참피이엘시이
스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스
스미스클라인 비참 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 기딩스, 스미스클라인비이참피이엘시이, 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스, 스미스클라인 비참 코포레이션 filed Critical 피터 기딩스
Publication of KR20000036039A publication Critical patent/KR20000036039A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
KR1019997002030A 1996-09-12 1997-09-08 방출 조절된 [Ｒ-(Ｚ)]-α-(메톡시이미노)-α-(1-아자비시클 KR20000036039A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition
GB9619074.9 1996-09-12

Publications (1)

Publication Number Publication Date
KR20000036039A true KR20000036039A (ko) 2000-06-26

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997002030A KR20000036039A (ko) 1996-09-12 1997-09-08 방출 조절된 [Ｒ-(Ｚ)]-α-(메톡시이미노)-α-(1-아자비시클

Country Status (22)

Country Link
EP (1) EP0929301A2 (id)
JP (1) JP2001500150A (id)
KR (1) KR20000036039A (id)
CN (2) CN1235544A (id)
AR (1) AR008176A1 (id)
AU (1) AU724086B2 (id)
BR (1) BR9711734A (id)
CA (1) CA2265661A1 (id)
CO (1) CO5031291A1 (id)
CZ (1) CZ83299A3 (id)
GB (1) GB9619074D0 (id)
HU (1) HUP9904401A3 (id)
ID (1) ID19589A (id)
IL (1) IL128781A0 (id)
MA (1) MA24359A1 (id)
NO (1) NO991194L (id)
NZ (1) NZ334268A (id)
PE (1) PE2499A1 (id)
PL (1) PL332074A1 (id)
TR (1) TR199900505T2 (id)
WO (1) WO1998010762A2 (id)
ZA (1) ZA978133B (id)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
AU748396C (en) * 1998-03-11 2003-01-23 Smithkline Beecham Corporation Composition
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2796840B1 (fr) * 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
EP1628642B2 (en) * 2003-05-14 2013-01-23 Aptalis Pharma Limited Controlled drug release composition resistant to in vivo mechanic stress
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
CA2576386A1 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
PL1789021T3 (pl) 2004-08-13 2012-04-30 Boehringer Ingelheim Int Preparat tabletkowy o przedłużonym uwalnianiu zawierający pramipeksol lub jego farmaceutycznie dopuszczalną sól
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0392803B1 (en) * 1989-04-13 2004-06-16 Beecham Group p.l.c. Novel compounds
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.

Also Published As

Publication number Publication date
BR9711734A (pt) 1999-08-24
ID19589A (id) 1998-07-23
CO5031291A1 (es) 2001-04-27
EP0929301A2 (en) 1999-07-21
HUP9904401A2 (hu) 2000-06-28
IL128781A0 (en) 2000-01-31
CN1235544A (zh) 1999-11-17
TR199900505T2 (id) 1999-06-21
PL332074A1 (en) 1999-08-30
CN1446535A (zh) 2003-10-08
NO991194D0 (no) 1999-03-11
AR008176A1 (es) 1999-12-09
CZ83299A3 (cs) 1999-08-11
HUP9904401A3 (en) 2001-03-28
NO991194L (no) 1999-03-11
WO1998010762A3 (en) 1998-06-04
MA24359A1 (fr) 1998-07-01
CA2265661A1 (en) 1998-03-19
AU724086B2 (en) 2000-09-14
NZ334268A (en) 2000-10-27
ZA978133B (en) 1999-04-12
GB9619074D0 (en) 1996-10-23
WO1998010762A2 (en) 1998-03-19
JP2001500150A (ja) 2001-01-09
AU4128897A (en) 1998-04-02
PE2499A1 (es) 1999-03-24

Similar Documents

Publication Publication Date Title
US6468560B2 (en) Controlled release dosage form of [R-(Z)]-α-(methoxyimino)-α-(1-azabicyclo[2.2.2]oct-3yl) acetonitrile monohydrochloride
EP0605174B1 (en) Delayed, Sustained-release pharmaceutical preparation
KR100437105B1 (ko) 방출 조절형 갈란타민 조성물
US8703186B2 (en) Abuse-resistant oral dosage forms and method of use thereof
US4904476A (en) Formulations providing three distinct releases
US4794001A (en) Formulations providing three distinct releases
CA1264296A (en) Formulations providing three distinct releases
EP0660705B1 (en) Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
EP0239361B1 (en) Sustained-release pharmaceutical preparation
US20040228915A1 (en) Oral extended release compressed tablets of multiparticulates
CA2717456A1 (en) Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
CS268819B2 (en) Method of particles production with effective substance's controlled loosening
PL188834B1 (pl) Farmaceutyczne formulacje zawierające tramadol lub jego fizjologicznie akceptowane sole oraz sposóbwytwarzania tych formulacji
PL200816B1 (pl) Powleczony rdzeń o opóźnionym uwalnianiu dający impuls czasowy uwalniania i farmaceutyczna postać dawkowana
US20020156133A1 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
KR20090091084A (ko) 방출성이 제어된 약제학적 제제
KR20000036039A (ko) 방출 조절된 [Ｒ-(Ｚ)]-α-(메톡시이미노)-α-(1-아자비시클
US20030099710A1 (en) Granule modulating hydrogel system
KR101990951B1 (ko) 리바스티그민 함유 서방출 의약조성물
US8173164B2 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
KR20050114921A (ko) 방출제어형 약제학적 조성물
MXPA99002404A (en) Controlled release dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2. 2]oct-3-yl)acetonitrile monohydrochloride
WO2009047800A2 (en) Oral controlled release composition of carvedilol
KR20040045485A (ko) 항경련제가 간격을 두고 배치된 약물전달계
US20140112995A1 (en) Multi-layered, multiple unit pharmaceutical compositions

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application